JPMorgan Chase & Co. restated their sell rating on shares of Puma Biotechnology (NASDAQ:PBYI) in a report issued on Monday morning, AnalystRatings.com reports. They currently have a $13.00 price objective on the biopharmaceutical company’s stock.

PBYI has been the topic of a number of other reports. ValuEngine raised shares of Puma Biotechnology from a sell rating to a hold rating in a report on Thursday, August 1st. Barclays dropped their price objective on shares of Puma Biotechnology from $21.00 to $9.00 and set an underweight rating on the stock in a report on Friday, August 9th. Cowen reissued a hold rating and set a $25.00 price objective on shares of Puma Biotechnology in a report on Friday, August 9th. Zacks Investment Research lowered shares of Puma Biotechnology from a buy rating to a hold rating in a report on Wednesday, May 1st. Finally, Goldman Sachs Group dropped their price objective on shares of Puma Biotechnology from $29.00 to $24.00 and set a neutral rating on the stock in a report on Wednesday, May 29th. They noted that the move was a valuation call. Three investment analysts have rated the stock with a sell rating and ten have issued a hold rating to the company. The stock presently has an average rating of Hold and a consensus target price of $22.56.

NASDAQ PBYI opened at $9.43 on Monday. The firm’s fifty day simple moving average is $10.76 and its two-hundred day simple moving average is $23.15. The company has a current ratio of 2.53, a quick ratio of 2.50 and a debt-to-equity ratio of 4.08. Puma Biotechnology has a 12-month low of $8.45 and a 12-month high of $50.75. The firm has a market capitalization of $366.80 million, a P/E ratio of -3.15 and a beta of 1.73.

Puma Biotechnology (NASDAQ:PBYI) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.97) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.90) by ($0.07). Puma Biotechnology had a negative return on equity of 224.11% and a negative net margin of 32.23%. The firm had revenue of $53.90 million during the quarter, compared to analysts’ expectations of $53.40 million. During the same period in the prior year, the firm posted ($0.59) earnings per share. Puma Biotechnology’s revenue for the quarter was up 6.1% compared to the same quarter last year. As a group, sell-side analysts predict that Puma Biotechnology will post -2.48 earnings per share for the current fiscal year.

In other news, insider Alan H. Auerbach sold 12,715 shares of the business’s stock in a transaction on Monday, July 22nd. The shares were sold at an average price of $9.98, for a total transaction of $126,895.70. Following the sale, the insider now directly owns 4,189,525 shares of the company’s stock, valued at $41,811,459.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders have sold 14,299 shares of company stock worth $146,360 over the last three months. Corporate insiders own 21.80% of the company’s stock.

A number of large investors have recently bought and sold shares of PBYI. Bank of Montreal Can boosted its holdings in Puma Biotechnology by 577.6% in the second quarter. Bank of Montreal Can now owns 2,602 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 2,218 shares during the last quarter. Quantamental Technologies LLC purchased a new stake in Puma Biotechnology in the second quarter valued at $56,000. CWM Advisors LLC purchased a new stake in Puma Biotechnology in the second quarter valued at $156,000. BB&T Securities LLC boosted its holdings in Puma Biotechnology by 22.9% in the second quarter. BB&T Securities LLC now owns 13,397 shares of the biopharmaceutical company’s stock valued at $170,000 after purchasing an additional 2,499 shares during the last quarter. Finally, Metropolitan Life Insurance Co. NY boosted its holdings in Puma Biotechnology by 383.0% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 9,698 shares of the biopharmaceutical company’s stock valued at $197,000 after purchasing an additional 7,690 shares during the last quarter. 81.41% of the stock is currently owned by institutional investors.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous).

See Also: How does equity income fit into an investing strategy?

Analyst Recommendations for Puma Biotechnology (NASDAQ:PBYI)

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.